Romplio 125 powder for injection 1's belongs to the class of 'platelet-stimulating agents' primarily used to treat chronic immune thrombocytopenia in adults who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Immune thrombocytopenia, often called idiopathic thrombocytopenic purpura (ITP), is an immune disorder characterised by low platelet counts.

Romplio 125 powder for injection 1's contains 'Romiplostim,' which is a thrombopoietin receptor agonist that functions similarly to thrombopoietin. Romplio 125 powder for injection 1's promotes platelet formation by activating the thrombopoietin receptor. Thereby, Romplio 125 powder for injection 1's helps treat immune thrombocytopenia effectively.

Romplio 125 powder for injection 1's will be administered by the healthcare professional. In some cases, Romplio 125 powder for injection 1's may cause common side effects like headache, joint pain, dizziness, trouble sleeping, muscle tenderness or weakness, pain in the arms and legs and indigestion. These side effects may vary individually. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Notify your doctor if you have allergic reactions to Romplio 125 powder for injection 1's or other medications. You must inform your doctor if you have leukaemia (blood or bone marrow cancer), bleeding or clotting disorders, or heart, kidney, or liver problems. Romplio 125 powder for injection 1's is not recommended during pregnancy unless indicated by the doctor. Romplio 125 powder for injection 1's may make you dizzy; hence drive or operate machinery only when you are alert. Romplio 125 powder for injection 1's is not recommended for use during breastfeeding.

Romplio 125 powder for injection 1's contains 'Romiplostim' which belongs to the class of 'thrombopoietin receptor agonists' used to treat low blood platelet count in patients with immune thrombocytopenia. Romplio 125 powder for injection 1's promotes platelet formation by activating the thrombopoietin receptor. Thereby, Romplio 125 powder for injection 1's helps treat immune thrombocytopenia effectively.

Before beginning Romplio 125 powder for injection 1's, notify your doctor if you have had any allergic reactions to Romplio 125 powder for injection 1's or any other medications. You must notify your doctor if you have blood or bone marrow cancer (leukaemia), bleeding or clotting disorders, heart, kidney, or liver problems. Romplio 125 powder for injection 1's is not recommended during pregnancy unless indicated by the doctor. Romplio 125 powder for injection 1's may make you dizzy hence do not attempt to drive or operate machinery until you are physically stable and mentally alert. Romplio 125 powder for injection 1's should never be used to normalize platelet counts; Romplio 125 powder for injection 1's should only be used in ITP patients whose thrombocytopenia and clinical condition increase the risk of bleeding. Romplio 125 powder for injection 1's is not recommended for use during breastfeeding.